# US 2011/0300529 A1 · Detection of ifi16 in body fluids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300529 A1
- Document ID: US20110300529A1
- Status: Published application
- Kind: A1
- Application number: 13/139,318
- Filed: 2009-12-14
- Published: 2011-12-08
- Earliest claimed: 2008-12-12
- Assignees: NoToPharm srl
- Inventors: Michele Mondini; Santo Landolfo; Marisa Gariglio; Silvia Costa; Erica Miraglia; Francesca Gugliesi
- Web page: https://patentgrep.com/patent/US20110300529A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 2039/505: {comprising antibodies}
- C07K 16/24: against cytokines, lymphokines or interferons
- G01N 2333/186: Hepatitis C; Hepatitis NANB
- G01N 2800/101: Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/104: Lupus erythematosus [SLE]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to methods for the qualitative and/or quantitative determination of interferon inducible protein 16 (IFI 16) in an extracellular form.

## Claims

### Claim 1

An in vitro method for determining extracellular interferon inducible pro-tein 16 (IFI16) in a sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is a body fluid sample, e.g., blood, plasma or serum, or a supernatant of a tissue sample or a supernatant of a cell culture sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the determination comprises:
(a) contacting the sample with at least one receptor, which specifically binds to IFI16, and
(b) detecting the specific binding of the receptor to IFI16.

### Claim 4 (depends on 3)

The method of claim 3, wherein the sample is contacted with at least two receptors, which specifically bind to IFI16, wherein one of the re-ceptors is a detectable receptor and the other receptor is immobilized on a solid phase or carries a solid-phase binding group.

### Claim 5 (depends on 3)

The method of claim 3, wherein at least one receptor is an anti-body or an antigen-binding fragment thereof.

### Claim 6 (depends on 4)

The method of claim 4, wherein the detectable receptor carries a detectable labelling group, e.g. an enzymatic, fluorescent, radioactive or nucleic acid labelling group.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample is a human sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein the presence and/or an increased amount of extracellular IFI16 is indicative for a pathologic condition.

### Claim 9 (depends on 1)

The method of claim 1, wherein the presence and/or an increased amount of extracellular IFI16 is indicative of an autoimmune and/or inflammatory disorder.

### Claim 10 (depends on 9)

The method of claim 9, wherein the autoimmune disorder is selected from Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE) and Sjägren's Syndrome (SjS).

### Claim 11 (depends on 9)

The method of claim 9, wherein the disorder is selected from rheumat-oid arthritis.

### Claim 12 (depends on 1)

The method of claim 1, wherein the presence and/or an increased amount of extracellular IFI16 is indicative of an infective dis-order.

### Claim 13 (depends on 12)

The method of claim 12, wherein the infective disorder is HCV infection.

### Claim 14 (depends on 1)

The method of claim 1, further comprising determining of at least one additional diagnostic marker.

### Claim 15 (depends on 14)

The method of claim 14, wherein the at least one additional diagnostic marker is an anti-IFI16-autoantibody.
